We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
In Vivo Pharmacodynamics of β-Lactams/Nacubactam against Carbapenem-Resistant and/or Carbapenemase-Producing Enterobacter cloacae and Klebsiella pneumoniae in Murine Pneumonia Model.
- Authors
Hagihara, Mao; Kato, Hideo; Sugano, Toshie; Okade, Hayato; Sato, Nobuo; Shibata, Yuichi; Sakanashi, Daisuke; Hirai, Jun; Asai, Nobuhiro; Suematsu, Hiroyuki; Yamagishi, Yuka; Mikamo, Hiroshige
- Abstract
Carbapenem-resistant Enterobacterales (CRE) and carbapenemase-producing Enterobacterales (CPE) have become global threats. CRE− and CPE− derived infections have been associated with high mortality due to limited treatment options. Nacubactam is a β-lactamase inhibitor and belongs to the new class of diazabicyclooctane. The agent has an in vitro antimicrobial activity against several classes of β-lactamase-producing Enterobacterales. This study evaluated antimicrobial activity of combination therapies including β-lactams (aztreonam, cefepime, and meropenem) and nacubactam against four Enterobacter cloacae and six Klebsiella pneumoniae isolates with murine pneumonia model. Based on changes in bacterial quantity, antimicrobial activities of some regimens were assessed. Combination therapies including β-lactams (aztreonam, cefepime, and meropenem) with nacubactam showed enhanced antimicrobial activity against CRE E. cloacae (−3.70 to −2.08 Δlog10 CFU/lungs) and K. pneumoniae (−4.24 to 1.47 Δlog10 CFU/lungs) with IMP-1, IMP-6, or KPC genes, compared with aztreonam, cefepime, meropenem, and nacubactam monotherapies. Most combination therapies showed bacteriostatic (−3.0 to 0 Δlog10 CFU/lungs) to bactericidal (<−3.0 Δlog10 CFU/lungs) activities against CRE isolates. This study revealed that combination regimens with β-lactams (aztreonam, cefepime, and meropenem) and nacubactam are preferable candidates to treat pneumonia due to CRE and CPE.
- Subjects
ENTEROBACTER cloacae; KLEBSIELLA pneumoniae; AZTREONAM; CEFEPIME; MEROPENEM
- Publication
Antibiotics (2079-6382), 2021, Vol 10, Issue 10, p1179
- ISSN
2079-6382
- Publication type
Article
- DOI
10.3390/antibiotics10101179